Abstract:Our understanding of infection biology is based on experiments in which pathogen or host proteins are perturbed by small compound inhibitors, mutation, or depletion. This approach has been remarkably successful, as, for example, demonstrated by the independent identification of the endosomal membrane protein Niemann-Pick C1 as an essential factor for Ebola virus infection in both small compound and insertional mutagenesis screens (Côté, Nature 477:344-348, 2011; Carette et al., Nature 477:340-343, 2011). However, many aspects of host-pathogen interactions are poorly understood because we cannot target all of the involved molecules with small molecules, or because we cannot deplete essential proteins. Single domain antibody fragments expressed in the cytosol or other organelles constitute a versatile alternative to perturb the function of any given protein by masking protein-protein interaction interfaces, by stabilizing distinct conformations, or by directly interfering with enzymatic activities. The variable domains of heavy chain-only antibodies (VHHs) from camelid species can be cloned from blood samples of animals immunized with the desired target molecules. We can thus exploit the ability of the camelid immune system to generate affinity-matured single domain antibody fragments to obtain highly specific tools. Interesting VHH candidates are typically identified based on their affinity toward immobilized antigens using techniques such as phage display.The phenotypical screening approach described here allows the direct identification of VHHs that prevent infection of cells with influenza A virus (IAV) or other pathogens. The VHH repertoire is cloned into a lentiviral vector, which is used to generate pseudo-typed lentivirus particles. Target cells are transduced with the lentivirus, so that every cell inducibly expresses a different VHH. This cell collection is then challenged with a lethal dose of virus. Only the cells which express a VHH that prevents infection by targeting virus proteins or host cell components essential for infection will survive. We can thus identify critical target molecules including vulnerable epitopes and conformations, render target molecules accessible to informative perturbation studies, and stabilize intermediates of virus entry for detailed analysis.

Progress on Pseudotyped Virus in Application

Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies

Pseudotyped Viruses for Coronaviruses

Pseudotyped Viruses for Mammarenavirus

Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses

Pseudotyped Viruses for Marburgvirus and Ebolavirus

Preliminary application of a coronavirus pseudovirus system

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Construction and applications of SARS-CoV-2 pseudoviruses: a mini review

Molecular Engineering of Virus Tropism

Phenotypic Lentivirus Screens to Identify Antiviral Single Domain Antibodies

Virus stealth technology: Tools to study virus cell-to-cell transmission

Transneuronal Circuit Analysis with Pseudorabies Viruses

Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins

Recapitulation of the Powassan virus life cycle in cell culture

Virus-derived Materials: Bury the Hatchet with Old Foes.

Viral Approaches to Study the Mammalian Brain: Lineage Tracing, Circuit Dissection and Therapeutic Applications

Characterization of pseudotyped viruses coated with hemagglutinin of H5N1 avian influenza

Characterization of Classical Swine Fever Virus Entry by Using Pseudotyped Viruses: E1 and E2 Are Sufficient to Mediate Viral Entry.

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Progress on Techniques of Virus Receptors